deltatrials
Completed PHASE4 INTERVENTIONAL 2-arm NCT05127486

A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine (CHALLENGE-MIG)

A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine

Sponsor: Eli Lilly and Company

Conditions Episodic Migraine Migraine
Interventions Galcanezumab Placebo Rimegepant
Updated 21 times since 2021 Last updated: Jun 17, 2024 Started: Dec 6, 2021 Primary completion: May 23, 2023 Completion: May 23, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Episodic Migraine and Migraine and is currently completed. Eli Lilly and Company leads this study, which shows 21 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Sep 2023 · 3 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Sep 2023 — Jul 2024 [monthly]

    Completed PHASE4

    Status: Active Not Recruiting → Completed

  5. Jun 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE4

▶ Show 16 earlier versions

  1. May 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE4

    Status: Recruiting → Active Not Recruiting

  2. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE4

  3. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE4

  4. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE4

  5. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE4

  6. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE4

  7. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE4

  8. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE4

  9. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE4

  10. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE4

  11. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE4

  12. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE4

  13. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE4

  14. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE4

  15. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  16. Dec 2021 — Jan 2022 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Amherst, United States , Ann Arbor, United States , Atlanta, United States , Austin, United States , Avon, United States , Banning, United States , Bellevue, United States , Boston, United States , Canton, United States and 64 more locations